{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:29:30Z","timestamp":1761514170045},"reference-count":72,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"Roswell Park Cancer Institute and National Cancer Institute","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]},{"name":"RPCI Alliance Foundation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,4,30]]},"DOI":"10.2217\/fon-2017-0459","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T10:06:34Z","timestamp":1521108394000},"page":"963-978","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["Advances in Immunotherapy for Acute Myeloid Leukemia"],"prefix":"10.1080","volume":"14","author":[{"given":"Amanda","family":"Przespolewski","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andras","family":"Szeles","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"},{"name":"Semmelweis University, Budapest, \u00dcll\u0151i \u00fat 26, 1085, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S","family":"Wang","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.14"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.25"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0519-7"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612721"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201405353"},{"key":"e_1_3_2_8_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Kenderian S","year":"2016","unstructured":"Kenderian S , RuellaM, ShestovaOet al. Leukemia stem cells are characterized by CLEC12A expression and chemotherapy refractoriness that can be overcome by targeting with chimeric antigen receptor T cells. Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 3\u20136 December 2016."},{"issue":"220","key":"e_1_3_2_9_1","first-page":"1072","article-title":"Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia","volume":"128","author":"Chien C","year":"2016","unstructured":"Chien C , SauterCT, IshiiKet al. Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Am. Soc. Hematol.128(220), 1072 (2016).","journal-title":"Am. Soc. Hematol."},{"key":"e_1_3_2_10_1","volume-title":"21st Congress of the European Hematology Association","author":"Ploch P","year":"2016","unstructured":"Ploch P , KhanS, BhattiA, KrebsL, TheobaldM, HartwigUF. Exploring chimeric natural killer receptor NKP30 expressing human T lymphocytes for adoptive immunotherapy to acute leukemia. Presented at: 21st Congress of the European Hematology Association. Copenhagen, Denmark, 9\u201312 June 2016."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.328"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"e_1_3_2_14_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Rafiq S","year":"2016","unstructured":"Rafiq S , PurdonTJ, SchultzLM, BrentjensRJ. CD33-directed chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemia (AML). Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112748"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166891"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"e_1_3_2_18_1","unstructured":"ClinicalTrials.gov\n. https:\/\/clinicaltrials.gov\/ct2\/home."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403224"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_3_2_22_1","unstructured":"OncLive\n. www.onclive.com\/web-exclusives\/fda-lifts-holds-on-offtheshelf-cart-trials."},{"key":"e_1_3_2_23_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Nikiforow S","year":"2016","unstructured":"Nikiforow S , WernerL, MuradJet al. Safety data from a first-in-human Phase I trial of NKG2D chimeric antigen receptor-T cells in AML\/MDS and multiple myeloma. Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.21"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.154"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.6.661"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123416"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.009"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.028"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1604"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501434"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000382019"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"e_1_3_2_35_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Dolstra H","year":"2015","unstructured":"Dolstra H , RoevenMWH, SpanholtzJet al. A Phase I study of allogeneic natural killer cell therapy generated from cord blood hematopoietic stem and progenitor cells in elderly acute myeloid leukemia patients. Presented at: Annual Meeting of the American Society of Hematology. FL, USA, 5\u20138 December 2015."},{"key":"e_1_3_2_36_1","volume-title":"Innate Killer Summit","author":"Feniger T","year":"2016","unstructured":"Feniger T , StuartR, CooleyS, SalhotraA. CNDO-109-activated allogeneic natural killer cells in patients with high risk acute myeloid leukemia in first complete remission (CR1): a Phase I study. Presented at: Innate Killer Summit. CA, USA, 16\u201318 May 2016 (Abstract D102)."},{"key":"e_1_3_2_37_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Boyiadzis M","year":"2016","unstructured":"Boyiadzis M , AghaM, RednerRLet al. Phase I clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells (aNK) in patients with refractory\/relapsed acute myeloid leukemia. Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.194"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.135301"},{"key":"e_1_3_2_40_1","volume-title":"21st Congress of the European Hematology Association","author":"Morgan M","year":"2016","unstructured":"Morgan M , DahlkeJ, OberschmidtOet al. Targeting CD123+ acute myeloid leukemia cells with redirected natural killer cells. Presented at: 21st Congress of the European Hematology Association. Copenhagen, Denmark, 10 June 2016."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28147"},{"key":"e_1_3_2_42_1","volume-title":"21st ISCT Annual Meeting (International Society for Cellular Therapy)","author":"Rafiq S","year":"2015","unstructured":"Rafiq S , PurdonTJ, SchultzLM, KlingemannH, BrentjensRJ. NK-92 cells engineered with anti-CD33 chimeric antigen receptors (CAR) for the treatment of acute myeloid leukemia (AML). Presented at: 21st ISCT Annual Meeting (International Society for Cellular Therapy). NV, USA, 27\u201330 May 2015."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0124-x"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11132"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-015-0002-1"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.10.014"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138016"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12282"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.39"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103710"},{"issue":"2","key":"e_1_3_2_51_1","first-page":"205","article-title":"Tumor-promoting versus tumor-antagonizing roles of gamma delta T cells in cancer immunotherapy: results from a prospective Phase I\/II trial","volume":"35","author":"Kunzmann V","year":"2012","unstructured":"Kunzmann V , SmetakM, KimmelBet al. Tumor-promoting versus tumor-antagonizing roles of gamma delta T cells in cancer immunotherapy: results from a prospective Phase I\/II trial. J. Immunol.35(2), 205\u2013213 (2012).","journal-title":"J. Immunol."},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0909-y"},{"key":"e_1_3_2_53_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Liu H","year":"2016","unstructured":"Liu H , ParkJH, FultonNet al. TCR clonal evolution in AML patients in morphologic remission treated with anti-PD1 antibody, nivolumab. Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 3 December 2016."},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.274"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0064"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/14653240500499507"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5257"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11063"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1195535"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00418"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1433-6"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3798.3798"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-780155"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1981-3"},{"key":"e_1_3_2_67_1","volume-title":"ASCO Annual Meeting","author":"Maslak PG","year":"2016","unstructured":"Maslak PG , DaoT, BernalYet al. Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR). Presented at: ASCO Annual Meeting. IL, USA, 3\u20137 June 2016."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24014"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.254"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.9.2315.bloodjournal8592315"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30696"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2549.2549"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2821.2821"},{"key":"e_1_3_2_74_1","volume-title":"Annual Meeting of the American Society of Hematology","author":"Lichtenegger F","year":"2016","unstructured":"Lichtenegger F , DeiserK, RotheMet al. Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a Phase I\/II trial and ex vivo enhancement by checkpoint blockade. Presented at: Annual Meeting of the American Society of Hematology. CA, USA, 5 December 2016."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:21Z","timestamp":1719125121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,4,30]]}},"alternative-id":["10.2217\/fon-2017-0459"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0459","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}